QRX 003
Alternative Names: QRX-003Latest Information Update: 18 May 2026
At a glance
- Originator Quoin Pharmaceuticals
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Serine protease inhibitors
-
Orphan Drug Status
Yes - Netherton Syndrome
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Netherton Syndrome
- Clinical Phase Unknown Peeling skin syndrome
- Preclinical Ichthyosis
- No development reported Palmoplantar keratoderma
Most Recent Events
- 07 May 2026 Quoin Pharmaceuticals plans to file an IND application for Peeling skin syndrome (In children) with US FDA in the second quarter of 2026
- 26 Mar 2026 Clinical trials in Netherton-Syndrome (In children) in Netherlands, New Zealand (Topical)
- 26 Mar 2026 Quoin Pharmaceuticals plans a phase III trial for Netherton Syndrome in 2026